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Relation
Gene Targeting and Subsequent Site-Specific
Transgenesis at the b-actin (ACTB) Locus
in Common Marmoset Embryonic Stem Cells
Seiji Shiozawa,1–3 Kenji Kawai,2 Yohei Okada,1 Ikuo Tomioka,2 Takuji Maeda,1,2 Akifumi Kanda,3
Haruka Shinohara,2 Hiroshi Suemizu,2 Hirotaka James Okano,1 Yusuke Sotomaru,3
Erika Sasaki,2 and Hideyuki Okano1
Nonhuman primate embryonic stem (ES) cells have vast promise for preclinical studies. Genetic modification in
nonhuman primate ES cells is an essential technique for maximizing the potential of these cells. The common
marmoset (Callithrix jacchus), a nonhuman primate, is expected to be a useful transgenic model for preclinical
studies. However, genetic modification in common marmoset ES (cmES) cells has not yet been adequately
developed. To establish efficient and stable genetic modifications in cmES cells, we inserted the enhanced green
fluorescent protein (EGFP) gene with heterotypic lox sites into the b-actin (ACTB) locus of the cmES cells using
gene targeting. The resulting knock-in ES cells expressed EGFP ubiquitously under the control of the endoge-
nous ACTB promoter. Using inserted heterotypic lox sites, we demonstrated Cre recombinase-mediated cassette
exchange (RMCE) and successfully established a monomeric red fluorescent protein (mRFP) knock-in cmES cell
line. Further, a herpes simplex virus-thymidine kinase (HSV-tk) knock-in cmES cell line was established using
RMCE. The growth of tumor cells originating from the cell line was significantly suppressed by the adminis-
tration of ganciclovir. Therefore, the HSV-tk=ganciclovir system is promising as a safeguard for stem cell
therapy. The stable and ubiquitous expression of EGFP before RMCE enables cell fate to be tracked when the
cells are transplanted into an animal. Moreover, the creation of a transgene acceptor locus for site-specific
transgenesis will be a powerful tool, similar to the ROSA26 locus in mice.
Introduction
Embryonic stem (ES) cells are unique cells derived fromearly embryo that are capable of both pluripotency and
self-renewal [1,2]. Genetic modification techniques, including
gene targeting and transgenesis, in mouse ES cells have been
used as important tools for many aspects of life science [3].
Recently, the establishment of both human ES cells and in-
duced pluripotent stem (iPS) cells has gained public attention
in terms of its application to stem cell therapy as a potential
source of donor cells [4–6]. For the clinical use of these stem
cells, however, thorough preclinical studies using nonhuman
primate models are essential to evaluate efficacy and safety.
Genetic modification techniques would be a powerful tool in
such studies. For instance, the introduction of a reporter gene
expression cassette would enable donor cells to be observed
and tracked to estimate the utility of stem cell therapy in
degenerative disease models such as spinal cord injury,
Parkinson’s disease, or myocardial infarction. Further, loss-of-
function and gain-of-function studies would enable the func-
tions of genes involved in tissue regeneration to be investigated.
However, transgenesis and gene targeting in primate ES
cells, including human ES cells, remain difficult mainly
because of the obscurity of cell cultures and the low trans-
fection efficiency. Also, the fact that transgenes are often
silenced in primate ES cells is another major problem [7,8].
The common marmoset (Callithrix jacchus), a type of new
world monkey, has several advantages for use as an exper-
imental primate [9,10]. These advantages include their small
size (250–400 g), ease of breeding, and high reproductive
efficiency (average of 4 pups=year from a breeding pair).
Moreover, we have recently developed transgenic common
marmosets, in which the transgene is transmitted through
the germ line [11]. Therefore, the common marmoset is
strongly expected to be useful as a nonhuman primate model
for human diseases in preclinical studies. Our group previ-
ously reported the successful establishment of common
marmoset ES (cmES) cell lines [12,13]. The cmES cells share
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biological characteristics with human and other primate ES
cells such as marker gene expression, cytokine response, and
differentiation ability, including teratoma formation. None-
theless, genetic modification techniques in cmES cells have
not yet been developed.
Recombinase-mediated cassette exchange (RMCE) is a
transgenic strategy using recombinase activity [14–16].
RMCE enables the site-specific integration of a transgene
efficiently by inserting a cassette flanked by a pair of het-
erospecific lox sites into a genomic locus in advance [17–20].
This method is highly advantageous relative to conventional
transgenesis using nonhomologous end joining because of its
predictable, reproducible, and stable expression from a sin-
gle copy transgene. Therefore, this transgenic strategy is
feasible for research using primate ES cells [21–24].
In this report, we demonstrated the insertion of a transgene
cassette carrying enhanced green fluorescent protein (EGFP)
flanked by loxP and loxPV into the b-ACTIN (ACTB) locus
of cmES cells using gene targeting [25–27]. The resulting
ACTBþ=EGFP cmES cell line expressed EGFP ubiquitously
under the control of the endogenous ACTB promoter before
RMCE. Hence, this cell line was useful for transplantation
experiments as a source of donor cells. We then performed
RMCE in the ACTBþ=EGFP cmES cells and showed the correct
exchange of the EGFP transgene with the monomeric red
fluorescent protein (mRFP) gene. Therefore, RMCE in this cell
line is useful for site-specific transgenesis in cmES cells. Fur-
ther, we also established a Herpes simplex virus-thymidine
kinase (HSV-tk) knock-in cmES cell line using RMCE. The
HSV-tk gene is a suicidal gene derived from herpes simplex
virus 1, which converts ganciclovir (GCV), a harmless pro-
drug, into toxic metabolites and selectively eliminates HSV-tk
gene-expressing cells [28]. TheHSV-tk knock-in cmES cell line
was capable of forming tumors, and tumor growth was sig-
nificantly suppressed by GCV administration. Therefore, this
HSV-tk=GCV system is a promising safeguard against possi-
ble tumorigenesis during stem cell therapy.
Materials and Methods
Cell culture
cmES cells (CMES40) were cultured on 50-Gy g-irradiated
mouse embryonic fibroblast feeder cells in ES medium (ESM)
which consisted of Knockout Dulbecco’s modified Eagle’s me-
dium (Invitrogen, Carlsbad CA) supplemented with 20%
Knockout SerumReplacement (Invitrogen), 0.1mMMEMNon-
Essential AminoAcids Solution (Sigma-Aldrich, St. Louis,MO),
2mM l-glutamine (Invitrogen), 0.1mM b-mercaptoethanol
(2-ME; Sigma-Aldrich), and 10ng=mL basic fibroblast growth
factor (bFGF; Wako Pure Chemical Industries Ltd., Osaka,
Japan).
For cmES cell splitting, the cells were treated with 10mM
Y27632 (Merck, Darmstadt, Germany) in ESM at 378C for 1 h,
then washed in phosphate-buffered saline (PBS), and disso-
ciated using 0.25% trypsin–ethylenediaminetetraacetic acid
(Invitrogen). The dissociated cells were seeded onto new
mouse embryonic fibroblast feeder cells.
Construction of targeting vector
A targeting vector was constructed to insert the exchange-
able transgene cassette into the 30 UTR of the marmoset
ACTB gene. The genomic DNA sequence of the putative C.
jacchus ACTB locus, which contains an exon–intron structure
homologous to human and mouse ACTB loci, was identified
from the C. jacchus genome database (Callithrix_jucchus-2.0.2:
the Genome Sequencing Center at Washington University
School of Medicine in St. Louis, http:==genome.wustl.edu=
pub=organism=Primates=Callithrix_jacchus=).
The 2.4-kb fragment containing exon 1–6 of the C. jacchus
ACTB gene and the 5.4 kb fragment downstream of the stop
codon were obtained using polymerase chain reaction (PCR)
as the 50 arm and the 30 arm, respectively. PCR was per-
formed using special primers and genomic DNA as tem-
plates, and then cloned using the Zero blunt TOPO PCR
Cloning kit (Invitrogen). These fragments were ligated with
the vector pPV-SE2N, which has an internal ribosome entry
site (IRES), EGFP, Furin-2A (F2A) [29], and neomycin-resistant
gene (Neo) flanked by loxP and loxPV.
Introduction of targeting vector
Forty micrograms of linearized targeting vector was in-
troduced with 100 mL of Lipofectamine LTX into sub-
confluent cmES cells in a 10-cm2 culture plate (5–7106 cells)
according to the manufacturer’s instructions (Invitrogen). At
16–24 h after transfection, the cells were dissociated and re-
seeded onto new feeder cells resistant to neomycin (day 1).
On day 3, the medium was changed to ESM containing
25 mg=mL of G418 (Invitrogen). The next day, the concen-
tration of G418 was increased to 50mg=mL. At days 12–14,
the G418-resistant colonies were selected and mechanically
dissociated by pipetting. The dissociated cells were reseeded
onto new feeder cells and partly onto a cell culture plate
without feeder cells for DNA preparation.
To detect the homologous recombinants, genomic DNA
was prepared using the DNeasy mini kit (Qiagen, Venlo, The
Netherlands) and double-digested with BamHI and EcoRI.
Southern blotting was performed using a DIG High Prime
DNA Labeling & Detection Starter Kit II (Roche Applied
Science, Manheim, Germany). For the 50 external probe, a
0.6-kb fragment was amplified using a PCR DIG Probe
Synthesis Kit (Roche Applied Science) using the primer pair
50-CATTCAGCAGCGTGGAGCTC and 50-AACTTTCCCAG
CCTGTCTAC. Single copy integration of the targeting vector
was confirmed using Southern blotting with BamHI-digested
genomic DNA and the EGFP probe.
Karyotyping, alkaline phosphatase staining,
and immunocytochemistry
The chromosome number and karyotype of the cmES cells
(passage number, 55) were analyzed as reported previously
[12,30]. For alkaline phosphatase staining, the cells were
fixed with 4% paraformaldehyde for a minute at room
temperature and washed twice with PBS(), then stained
with sigmaFAST BCIP=NBT kit (Sigma-Aldrich).
Immunocytochemistry for SSEA-4, TRA-1-60, and TRA-1-81
were performed as previously reported [12]. For the immu-
nocytochemistry of NANOG, OCT3=4, SOX17, CD31, neural
cell adhesion molecule (NCAM), and GFP, the cells were
fixed with 100% ethanol for 10min at room temperature.
After antigen retrieval using heat only for NCAM, the cells
were incubated with primary antibodies against NANOG
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(RCAB0001P; Reprocell, Kanagawa, Japan),OCT3=4 (MAB4419;
Millipore, Billerica, MA), SOX17 (AF1924; R&D Systems,
Minneapolis, MN), CD31 (N1596; Dako, Carpinteria, CA),
and NCAM (413331; Nichirei Biosciences, Tokyo, Japan) at
dilutions of 1:200, 1:200, 1:20, 1:1, and1:1, respectively, overnight
at 48C, followed by incubationwithAlexa 594–conjugated anti-
goat IgG for SOX17, Alexa 594–conjugated anti-rabbit IgG
for NANOG, and Alexa 594–conjugated anti-mouse IgG
for OCT3=4, CD31, and NCAM. After washing with PBS(),
the cells were incubated with Alexa 488–conjugated anti-
GFP antibody (Invitrogen) for 1 h at room temperature, and
washed with PBS() 3 times, and then examined under a
fluorescence microscope.
Embryoid body formation and flow cytometry
For embryoid body (EB) formation, dissociated cmES cells
were resuspended in ESM without bFGF and seeded onto
low cell-binding dishes (Nalge Nunc, Rochester, NY). After
15 days of suspension culture, the EBs were dissociated and
resuspended in PBS() with 2.5 mg=mL of propidium iodide
and analyzed for GFP fluorescence using a FACSCalibur
(Becton Dickinson, Franklin Lakes, NJ).
In vitro differentiation
For endoderm differentiation, undifferentiated cmES cells
were cultured in ESM containing 100 ng=mL of Activin A
(R&D Systems) for 5 days. For mesoderm differentiation, the
EBs were formed for 7 days and transferred onto chamber
slides in ESM containing 50 ng=mL of vascular endothelial
growth factor-A (Peprotech, Rocky Hill, NJ) for the next 7
days. For ectoderm differentiation, cmES cells were cultured
onto gelatin-coated chamber slide for 21 days in 10 ng=mL of
bFGF and 0.5 mM A83-01 (Wako Pure Chemical Industries
Ltd.) and N2 and B27 supplement (Invitrogen)-containing
Knockout Dulbecco’s modified Eagle’s medium.
Teratoma formation
Teratoma formation was performed as previously de-
scribed [12]. Briefly, 5–10106 cmES cells were injected
subcutaneously or into the kidney capsule of NOD=shi-scid,
IL-2Rgnull (NOG)mice [31]. About 5weeks after injection, the
tumors were collected and fixed in neutral-buffered formalin
and embedded in paraffin. The paraffin blocks were sectioned
and subjected to immunohistochemical staining. Primary
antibodies against NCAM (clone: 1B6; Leica Microsystems,
Wetzlar, Germany), vimentin (clone: SP20; Nichirei Bios-
ciences), a-fetoprotein (AFP, clone: C3; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), and GFP (rabbit polyclonal anti-GFP
antibody; Abcam, Cambridge, United Kingdom) were incu-
bated with the paraffin sections at dilutions of 1:200, 1:100,
1:100, and 1:4,000, respectively. The localization of the bound
monoclonal antibodies was detected using the universal
immunoenzyme polymer system (Histofine Simple Stain
MAX-PO; Nichirei Biosciences). The sections for NCAM and
vimentin were pretreated in an autoclave for antigen retrieval.
Suitable positive and negative controls were included.
Recombinase-mediated cassette exchange
For RMCE, a donor plasmid, pPV-BE-Red, consisting of
BGH poly A, the EF1 a promoter, and mRFP cDNA flanked
by loxP and loxPV was constructed [32]. Five micrograms of
the donor plasmid and 5 mg of the Cre expression plasmid
(pCAGGS-Cre) were cotransfected with Lipofectamine LTX
into subconfluent cmES cells in a well of a 6-well plate. The
next day, the cells were dissociated and reseeded onto new
feeder cells. Resulting colonies that included mRFP-positive
cells was selected, dissociated, and reseeded onto new feeder
cells. A colony consisting of only mRFP-positive cells was
isolated, and an mRFP-positive cell line was established.
Genotyping was performed by genomic PCR using the fol-
lowing primer pair: EGFP, 50-GCACAAGCTGGAGTA
CAACTACAACAGC and 50-TCACGAACTCCAGCAGGA
CCATG; mRFP, 50-CGAGGACGTCATCAAGGAGT and
50-CTTGGCCATGTAGGTGGTCT; Cre, 50-CGTACTGACGG
TGGGAGAAT and 50-CCCGGCAAAACAGGTAGTTA.
For the HSV-tk donor plasmid, the IRES-driven HSV-tk
transgene was connected upstream of the IRES-driven
Hygromycin-resistant gene and was flanked by loxP and
loxPV (pPV-TK). The Cre expression plasmid and pPV-TK
were introduced into BR29 cells, as described above, and the
cells were reseeded onto hygromycin-resistant feeder cells.
The cells were selected using 25mg=mL of hygromycin (Wako
Pure Chemical Industries Ltd.) for 2 weeks, and hygromycin-
resistant colonies were selected. The IRES-HSV-tk transgene
was detected using PCR with 50-GTAATGACAAGCGC
CCAGAT and 50-ATGCTGCCCATAAGGTATCG.
GCV administration in vitro and in vivo
Cultured HSV-tk knock-in cmES cells and BR29 cells were
dissociated and cultured with or without 1mM GCV on
feeder cells.
For the in vivo study, 5105–10105 HSV-tk knock-in
cmES cells were injected into NOG mice subcutaneously.
One and half months after injection, 18 out of 20 NOG mice
developed tumors. The tumor diameter was measured
(day 10), and the mice were divided into 2 groups: a GCV-
treatment group and a control group. The GCV-treatment
group was given 50mg=kg of GCV intraperitoneally on
days 2 and 0. The tumor diameter was measured 1 or 2
times per week. The tumor volume was calculated using the
formula (V¼ ab2=2), where a is the larger and b is the smaller
axis of the tumor [33]. The tumor growth rate relative to
the tumor volume on day 10 was calculated. On day 19, the
tumors were collected and the specimens were prepared as
described above. Immunostaining using anti-Ki-67 antibody
(MIB-1; N1633; Dako) was performed, and Ki-67-positive
and Ki-67-negative nuclei in 3 different areas of each slide
were counted automatically using DynamicCellCount soft-
ware (Keyence, Osaka, Japan).
Results
Cloning of the common marmoset ACTB gene
First, to determine the ACTB genomic DNA sequence of
the common marmoset, we searched the Washington Uni-
versity GSC BLST server using the sequence for human
ACTB cDNA as a probe. As a result, several sequences were
hit, including obvious pseudogenes that did not have an
exon–intron structure. From these sequences, we selected
contig6614.25, which has a putative exon–intron structure
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and a TATA box and a CAAT box upstream of the putative
ATG, similar to the human ACTB gene (Fig. 1A) [34]. The
reconstructed open reading frame and amino acid sequence
from the genomic sequence were 94% and 100% identical to
those of the human ACTB gene, respectively (Fig. 1B). Thus,
we defined the sequence as the common marmoset ACTB
gene locus. Next, we designed the homology arms of the
targeting vector to insert an exchangeable transgene cassette
between the stop codon and the putative polyadenylation
signal sequence (Fig. 2A). The designed homology arms were
cloned from genomic DNA of the cmES cell line CMES40
using PCR. After confirmation of the sequence, the homol-
ogy arms were ligated into a backbone plasmid consisting of
a transgene cassette flanked by loxP and loxPV containing the
F2A peptide-linked EGFP gene and the Neomycin (G418)-
resistant gene (Neo) driven by IRES.
FIG. 1. Analysis of genomic
locus for the common mar-
moset ACTB gene. (A) Sche-
matic representation of the
genomic locus for the com-
mon marmoset ACTB gene
and the 50 sequence. The UTRs
and exons are represented by
the gray boxes and the black
boxes, respectively. The under-
lined sequences indicate the
exons. The open-boxed se-
quences indicate the putative
promoter and enhancer. The
first ATG in exon 2 is shaded.
(B) Comparison of the re-
constructed open reading
frame of the common mar-
moset ACTB gene (cjACTB)
versus the human ACTB gene
(hACTB) open reading frame.
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ACTB gene targeting in cmES cells
For gene targeting, the targeting vector was linearized
using AatII digestion and introduced into cmES cell CMES40
using Lipofectamine LTX. After selection with G418, 31 re-
sistant colonies from 2 transfections were obtained. These
colonies were selected and reseeded onto new feeder cells
and then expanded. Genomic DNAs were isolated from
some of the cells and analyzed using a Southern blot analysis
with the 50 external genomic probe to confirm homologous
recombination. As shown in Fig. 2B, 17 of the 21 clones that
were analyzed were homologous recombinants. All the
ACTBþ=EGFP cmES cell clones were EGFP positive, whereas
the other clones were EGFP negative except for one clone.
Three ACTBþ=EGFP cmES cell clones were used for the sub-
sequent analyses (No. 8, 21, and 29). Single copy integration
of the targeting vector was confirmed by detection of a single
band of the expected size using a Southern blot analysis with
the EGFP probe (Fig. 2C).
Characterization of ACTB þ=EGFP cmES cells
Out of the ACTBþ=EGFP cmES cell clones, clone No. 29 was
used for the subsequent experiments; this cell line was
named BR29. A karyotype analysis revealed the mainte-
nance of a normal karyotype (46, XX) in the BR29 cells even
after over 50 passages (Fig. 3A). This cell line forms typical
ES cell colonies and constitutively expressed EGFP (Fig. 3B).
Moreover, the cells were positive for alkaline phosphatase
staining, which is characteristic of undifferentiated ES cells
(Fig. 3C). To further confirm their undifferentiated state, the
expression of primate ES cell-specific surface antigens
(SSEA-4, TRA-1-60, and TRA-1-81) was examined using
immunocytochemistry. As shown in Fig. 3C, all 3 antigens
were expressed on the BR29 cells. Further, the expression of
the ES cell-specific transcription factors OCT3=4 and NA-
NOG was observed in the nuclei of the BR29 cells (Fig. 3D).
Therefore, this cell line was thought to retain an undiffer-
entiated state.
Differentiation ability of BR29 cells
To estimate their differentiation ability, undifferentiated
BR29 cells were transferred into a suspension culture
containing a differentiation medium. The BR29 cells spon-
taneously formed EBs, which expressed EGFP. No EGFP-
negative cells were found in the EB (Fig. 4A). Further, a flow
cytometry analysis confirmed ubiquitous EGFP expression in
EBs (Fig. 4B).
BR29 cells also showed directed differentiation into
derivatives of the three germ layers. As shown in Fig. 4C,
differentiation into SOX17-positive endoderm cells, CD31-
positive mesoderm cells, and NCAM-positive neuroectoderm
cells was observed. EGFP expression was persistently ob-
served in the differentiated state.
Next, a teratoma formation assay was performed to esti-
mate their differentiation ability in vivo. When cmES cells
were injected subcutaneously or into the kidney capsule of
immunodeficient mice, the mice developed tumors (Fig. 5A).
Immunohistochemistry of the tumors revealed that the
tumor contained derivatives of all three germ layers (Fig.
5B–G). EGFP expression strictly marked the tumor tissue
derived from the cmES cells (Fig. 5H, I).
FIG. 2. Gene targeting of the common marmoset ACTB gene locus. (A) Schematic representations of the wild-type common
marmoset ACTB gene locus, the targeting vector, and the targeted locus. (B) Southern blot analysis of BamHI and EcoRI
double-digested genomic DNA from G418-resistant clones using the 50 probe. WT, wild-type; KI, Knock-in. (C) Southern blot
analysis of the BamHI-digested genomic DNA from clone No. 8, 21, and 29 using the enhanced green fluorescent protein
(EGFP) probe shown in (A).
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Cre RMCE at the ACTB locus
The transgene inserted into the ACTB locus of the BR29
cells had 2 heterotypic lox sites, wild-type loxP and mutant
loxP, also known as loxPV or lox2272. Recombination by Cre
recombinase rarely occurs between these lox sites. None-
theless, if a DNA fragment is flanked by the same set of lox
sites, recombination occurs between each of the homologous
lox sites. As a result of this recombination, the EGFP trans-
gene cassette is replaced by the DNA fragment. To confirm
the exchange reaction in the cell line, we constructed a donor
plasmid EF1a promoter-driven mRFP expression cassette
flanked by heterotypic lox sites (pPV-BE-Red). A poly A
signal sequence was inserted upstream of the EF1a promoter
to terminate transcription from the endogenous ACTB gene
(Fig. 6A).
To examine the cassette replacement, the Cre expression
plasmid and pPV-BE-Red were cotransfected into BR29
cells using lipofection. As a result, a colony including
mRFP-positive cells was obtained. These mRFP-positive
cells lost their EGFP expression, indicating that RMCE
occurred properly (Fig. 6B). The colony including mRFP-
positive and EGFP-negative cells was selected and me-
chanically dissociated by pipetting, and then reseeded onto
new feeder cells. The mRFP-positive and EGFP-negative
cmES cell line was established by subsequent serial sub-
cloning based on mRFP expression (Fig. 6C). The cell line
maintained the expression of ES cell-specific markers
and showed a normal karyotype (Supplementary Fig. S1;
Supplementary Data are available online at www
.liebertonline.com=scd). Cassette exchange and the absence
of Cre expression plasmid integration were confirmed us-
ing genomic PCR (Fig. 6D).
Establishment of ACTBþ=HSV-tk cmES cells
using RMCE
Next, we tried to establish HSV-tk knock-in cmES cell lines
using RMCE (Fig. 7A). The cassette-replaced clones were
selected using hygromycin resistance. As a result, 6 clones
were obtained, all of which had lost their EGFP fluorescence.
The genotype was confirmed using genomic PCR (Fig. 7B).
The established clone No. 2, BR29-TK, showed an undiffer-
entiated phenotype and a normal karyotype (Supplementary
Fig. S1). To examine the sensitivity against GCV in BR29-TK,
they were cultured in the growth medium with or without
1 mM of GCV for 7 days. Whereas the BR29 cells grew and
formed colonies normally in the presence of GCV, the BR29-
TK cells could not grow in the medium containing 1mM of
GCV (Fig. 7C).
FIG. 3. BR29 cells retain a normal karyotype, an undifferentiated state, and express EGFP. (A) Karyotype analysis of the
ACTBþ=EGFP common marmoset embryonic stem (cmES) cell clone no. 29. (B) Phase-contrast microscopy (left) and fluores-
cence microscopy (right) of the ACTBþ=EGFP cmES colonies. Bar, 200mm. (C) Alkaline phosphatase (ALP) staining and
immunocytochemistry for SSEA-4, TRA-1-60, and TRA-1-81 inACTBþ=EGFP cmES cell clone no. 29. Bar, 200mm. (D)Detection of the
ES cell-specific transcription factors, NANOG and OCT3=4, using immunocytochemistry. Bars, 100 mm.
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To test the effect of GCV treatment on the growth of
HSV-tk-expressing tumors in vivo, BR29-TK cells were
subcutaneously injected into immunodeficient mice. About
1–1.5 months after injection, 18 of the 20 immunodeficient
mice developed a tumor. The tumor volume was measured
at each time period (Fig. 7D). Half of the tumor-bearing
mice were given 50mg=kg of GCV on days 2 and 0 (Fig.
7D). As shown in Fig. 7E, the growth rate of the tumor
was slightly decreased at 4 days after GCV administration.
Although the growth rate gradually increased from days 7
to 19, a significant suppression of tumor growth in re-
sponse to GCV treatment was observed. Subsequent
immunohistochemistry of the tumor revealed that although
Ki-67-positive growing tumor cells persisted within the
GCV treatment group, the number of Ki-67-positive cells
was less than that in the control group (Fig. 7F). Quanti-
tative analysis of the proportion of Ki-67-positive nuclei
against all the nuclei of these tumors confirmed a signifi-
cant reduction in Ki-67-positive cells in the GCV treatment
group (Fig. 7G).
Discussion
Primate, including human, and mouse ES cells have dif-
ferent biological properties in several aspects, such as gene
expression and their responses to growth factors. Mouse
epiblast stem cell (EpiSC) lines from early postimplantation
embryos have been shown to share some features with pri-
mate ES cells [35,36]. Therefore, primate ES cells are likely to
have mouse EpiSCs-like characteristics, rather than mouse
ES cell-like ones. Mouse EpiSCs are known to be highly in-
efficient at producing chimeric mice upon aggregation or
injection into host blastocysts, unlike mouse ES cells. Thus,
well-developed genetic modification techniques in mouse ES
cells were considered to be inapplicable to primate ES cells.
Further, a high frequency of transgene silencing in primate
ES cells has also been an obstacle for their use in basic re-
search and preclinical research using transgenes [7,8].
However, a recent report has shown that the identity
of mouse EpiSCs-like human ES cells can be rewired into
a more immature state that extensively shares defining
FIG. 4. BR29 cells can dif-
ferentiate into three germ lay-
ers in vitro without the loss of
EGFP expression. (A) Phase-
contrast microscopy (left) and
fluorescencemicroscopy (right)
of day 21 embryoid bodies
(EB). Bar, 500mm. (B) Flow cy-
tometric analysis of EGFP ex-
pression in day 15 EB.þ=EGFP
and þ=þ indicate the BR29
cells and wild-type cmES cells,
respectively. (C) Differentia-
tion of BR29 cells into three
germ layers. The right column
shows overlapping images for
each of the immunocytochem-
istry results (left, top, to bottom,
SOX17, CD31, and NCAM;
red) and the center column
(EGFP; green) with DAPI
staining (blue). Bars, 50mm.
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features with mouse ES cells [37]. Such a conversion of hu-
man ES cell characteristics was achieved through the ectopic
induction of some pluripotent factors combined with leuke-
mia inhibitory factor and the well-known 2i method [38],
which was used for the production of the first germline-
competent rat ES cells [39,40] using inhibitors of glycogen
synthase kinase 3b and the mitogen-activated protein kinase
(ERK1=2) pathway [37]. Thus, based on these technological
improvements, an increasing need exists for an efficient site-
specific transgenic system in primate ES cells for the future
generation of knock-in and knock-out primate animals.
In the present study, we built a site-specific transgenic
system using RMCE at the ACTB locus in cmES cells, en-
abling stable and ubiquitous transgene expression. For this
purpose, we first established a gene targeting technique
and inserted heterospecific lox sites with the EGFP transgene
into the ACTB locus. The targeted cmES cells retained the
undifferentiated ES cell characteristics, with a normal kar-
yotype and a three germ layer differentiation ability after
gene targeting, suggesting that our gene targeting method
does not affect the undifferentiated state of cmES cells (Figs.
4 and 5). In addition, the inserted EGFP transgene could be
replaced with another transgene cassette carrying the mRFP
gene through Cre recombinase.
The instability of transgene expression, such as silencing
or ectopic expression, mainly arises from a position effect of
the integration site and has often been problematic in mouse
transgenesis [41]. To circumvent this phenomenon, a site-
specific transgenesis strategy has been developed using the
ROSA26 locus. Although Irion et al. recently reported a hu-
man ROSA26 gene knock-in locus [42], whether an ubiqui-
tous expression pattern from the fetal to adult stage is
conserved in primates remains unclear. Another group also
established a versatile human ES cell lines for RMCE using
random integration with an exogenous promoter [23].
However, the expression pattern can never be predicted
in vivo using this method. On the other hand, the ACTB gene
is a typical housekeeping gene that is ubiquitously expressed
and has been used as a positive control of gene expression in
many aspects. Since the ACTB gene has a critical function in
cell homeostasis, latent haploinsufficiency may occur if an
allele is disrupted by the insertion of a transgene. Therefore,
we designed a targeting vector that inserted an IRES-driven
transgene into the 30 UTR of this gene to avoid any loss of
gene expression (Fig. 2A).
We adapted the lipofection method using Lipofectamine
LTX to introduce the targeting vector. Electroporation is
thought to be more effective for gene targeting in human ES
cells than chemical methods [43,44], although we first ex-
amined the use of electroporation to introduce the targeting
vector, the efficiency was quite low, and only one clone was
a homologous recombinant (data not shown). On the other
hand, 17 homologous recombinants out of 21 G418-resistant
clones were obtained using lipofection (Fig. 2B). Recently, a
notable improvement in viral vectors has made gene tar-
geting in human and cynomolgus monkey ES cells possible
through the use of helper-dependent adenoviral vector
(HDAdV) [45]. HDAdV permits the insertion of a large DNA
fragment with a high efficiency and has a low cytotoxicity,
compared with common AdV [46–48]. However, the prepa-
ration of HDAdV requires an advanced technique, making
this technique difficult to perform on a routine laboratory
basis. By contrast, lipofection is a relatively simple method
that requires neither specific, complicated techniques nor any
specific instruments. Thus, the lipofection method used in
this report is a promising tool for the targeting of other genes
in cmES cells.
FIG. 5. Teratoma formation of the BR29 cells. (A) Tumors
formed in the kidney capsule (left side) and normal kidney
(right side). Bar, 1 cm. (B–G) Immunohistochemistry of the
formed tumor. This tumor is comprised of a-fetoprotein
(AFP)-positive cells (B), vimentin-positive cells (D), and
neural cell adhesion molecule (NCAM)-positive cells (F),
indicating the endoderm, mesoderm, and ectoderm, respec-
tively. Hematoxylin–eosin (HE) staining is shown in (C, E,
G). Bars in (B) and (C), 50 mm. Bars in (D–G), 100mm. (H)
EGFP expression at the border between the teratoma tissue
and the normal kidney tissue. (I) HE staining of the serially
sectioned specimen shown in (H). Bars in (H) and (I), 200mm.
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The cassette replacement experiment showed that the
EGFP transgene was correctly replaced with the mRFP
transgene by cotransfection with the Cre expression plasmid
(Fig. 6B, D). The mRFP-positive cmES cell line was success-
fully established by serial subcloning without any drug se-
lection (Fig. 6C). This technique should facilitate the
establishment of various transgenic cmES cell lines with
stable and ubiquitous expression.
For therapeutic applications of ES cells or iPS cells as
sources of donor cells, the tumorigenic propensity of these
cells has been a major barrier [49,50]. Teratoma formation
ability is a native characteristic of these undifferentiated
pluripotent stem cells. Moreover, these cells may acquire an
even higher tumorigenic propensity as a result of mutations
or chromosomal abnormalities in cultured cells. Indeed, re-
current chromosomal abnormalities in cultured human ES
cells have been reported, and some of these abnormalities
have been associated with oncogenic transformation [51–54].
On the other hand, proving the chromosomal normality of all
donor cells is practically impossible in viable cells before
transplantation. To ensure the safety of stem cell therapy,
the application of the HSV-tk=GCV system has been pro-
posed [55,56]. The introduction of the HSV-tk gene into do-
nor cells in advance enables tumors originating from the
donor cells to be suppressed by the administration of GCV.
For this purpose, however, the transgene should be stably
expressed even after the cells have transformed into any cell
type. However, achieving the ubiquitous expression of the
transgene constantly is rather difficult using conventional
transgenesis with random integration. Our site-specific
transgenesis using the endogenous ACTB gene promoter is
especially suitable for this purpose. Thus, we established
an HSV-tk knock-in cmES cell line using RMCE. Using
drug selection, about 10 colonies were obtained. Of these, 6
clones were expanded and their genotypes were analyzed.
All the clones that were analyzed exhibited correct ex-
changes. This high efficiency of cassette exchange is prob-
ably due to the promoter-less strategy using an IRES
sequence, since most randomly integrated clones do not
express the transgene except for promoter trapping. BR29-
TK, an established HSV-tk knock-in cmES cell line, ex-
hibited sensitivity to GCV in vitro. This finding indicates
the expression of a functional HSV-tk gene. Next, we per-
formed tumor formation in immunodeficient mice using
BR29-TK. In the GCV administration group, the tumor
growth rate was significantly suppressed. An immuno-
histochemical analysis revealed that the number of Ki-
67-positive growing tumor cells was significantly lower
than that in the control group. Therefore, for therapeutic
application of ES cells or iPS cells, this HSV-tk constitutive
expression from the ACTB locus in donor cells is a prom-
ising countermeasure to the possible donor cell-derived
tumor formation upon transplantation. However, in this
experiment, the Ki-67-positive cells partially persisted de-
spite the administration of GCV (Fig. 7F). This result might
have arisen because a certain population of the cells that had
been in a quiescent state when GCV was administered sur-
vived and grew within our moderate GCV administration
FIG. 6. Cre recombinase-mediated cas-
sette exchange (RMCE) in BR29 cells. (A)
Schematic representation of the strategy
for RMCE at the ACTB locus. As a result of
cassette replacement, EGFP fluorescence is
lost instead of monomeric red fluorescent
protein (mRFP) positivity. BGHpA, bovine
growth hormone gene polyadenylation
signal; EF1a, human elongation factor 1a
gene promoter. (B) Fluorescence micros-
copy of mRFP (left) and EGFP (right) in a
colony obtained by RMCE. The arrowheads
indicate mRFP-positive and EGFP-negative
cells. (C) Phase-contrast microscopy (left)
and fluorescence microscopy (right) of the
established mRFP knock-in cmES cells.
Bar, 500mm. (D) Polymerase chain reaction
(PCR) analysis of the genomic DNA of the
mRFP Knock-in cmES cells (þ=mRFP),
BR29 cells (þ=EGFP). Cre indicates the Cre
expression plasmid used as a positive con-
trol for PCR.
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protocol. In many reports, the HSV-tk=GCV tumor
suppression system was given GCV once or twice a day for
5–14 days [57–61]. In our experiment, GCV was adminis-
tered only once on both days 2 and 0 to reduce adverse
effect-related damage to the animals, but this regimen was
sufficient to produce a tumor suppression effect. None-
theless, to eliminate the Ki-67-positive tumor cells com-
pletely, a longer GCV administration period is likely
needed. Further studies to assess the efficacy of this system
using disease model marmosets with states similar to those
experienced in clinical settings are expected.
In conclusion, we created a transgene acceptor site at the
ACTB locus of cmES cells for performing RMCE. This report
is the first to demonstrate gene targeting in cmES cells. This
cell line allows the efficient targeting of various transgenes
using Cre recombinase activity. The transgene expression
enabled by the endogenous ACTB promoter is ubiquitous
and stable. These techniques are expected to be useful for
FIG. 7. Establishment of her-
pes simplex virus-thymidine
kinase (HSV-tk) knock-in
cmES cell line using RMCE. (A)
Schematic representation of
HSV-tk knock-in ES cell line
using RMCE. The exchanged
clone loses EGFP expression
and acquires resistance to hy-
gromycin. (B) Genotyping re-
sults for hygromycin-resistant
clones using genomic PCR. (C)
In vitro study of sensitivity to
ganciclovir (GCV) in BR29-TK
cells (þ=HSV-tk). Bar, 200mm.
(D) Schedule of the in vivo
study for GCV administration
in tumors derived from BR29-
TK cells. The cells were injected
into immunodeficient mice and
developed into tumors after
about 1month. Thereafter,mice
harboring tumors were treated
with GCV or water as a control
on days 2 and 0. The tumor
volume was measured during
each time period. (E) Transi-
tions of tumor growth rate. The
arrows indicate the timing of
the administration. The graph
presents the mean of the rela-
tive values of the tumor volume
against that of day 10. The error
bars indicate the standard error
of the mean. The P values ob-
tained using the Student’s t-test
indicate a significant differ-
ence (*P< 0.05). (F) The mice
were sacrificed on day 20 and
the tumors were examined. The
upper panels show HE staining
of the control (left) and GCV-
treated (right) tumors. The mid-
dle and lower panels show Ki-67
immunostaining. Bars in the
upper and middle panel, 100mm.
Bar in the lower panel, 50mm. (G)Quantitative analysis ofKi-67-positive cells in the control andGCV-treated tumors. The results are
expressed as the percentage of the Ki-67-positive nuclei. The error bars indicate the standard error of the mean (GCV, n¼ 8;
Control, n¼ 10). P values obtained using the Student’s t-test indicate a significant difference (**P< 0.01).
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preclinical studies and stem cell biology using transgenes in
the common marmoset.
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